Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Other Non-Current Assets (2016 - 2025)

Avanos Medical's Other Non-Current Assets history spans 11 years, with the latest figure at $73.9 million for Q3 2024.

  • For Q3 2024, Other Non-Current Assets rose 301.63% year-over-year to $73.9 million; the TTM value through Sep 2024 reached $73.9 million, up 301.63%, while the annual FY2023 figure was $19.3 million, 9.66% up from the prior year.
  • Other Non-Current Assets for Q3 2024 was $73.9 million at Avanos Medical, up from $72.7 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $73.9 million in Q3 2024 and bottomed at $10.7 million in Q2 2020.
  • The 5-year median for Other Non-Current Assets is $16.3 million (2022), against an average of $24.1 million.
  • The largest annual shift saw Other Non-Current Assets fell 22.92% in 2021 before it skyrocketed 301.63% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $11.8 million in 2020, then skyrocketed by 39.83% to $16.5 million in 2021, then grew by 6.67% to $17.6 million in 2022, then grew by 9.66% to $19.3 million in 2023, then surged by 282.9% to $73.9 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Other Non-Current Assets are $73.9 million (Q3 2024), $72.7 million (Q2 2024), and $66.5 million (Q1 2024).